STOCK TITAN

Quanterix Corporation - QTRX STOCK NEWS

Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.

Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.

At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.

Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.

Quanterix's product lineup is diverse and includes:

  • Simoa platform
  • Assay Kits
  • LDTs & Assay Services
  • Simoa p-Tau 217
  • Simoa NfL LDT
  • Simoa p-Tau 181 LDT
  • HD-X Automated Immunoassay Analyzer
  • SR-X Biomarker Detection System
  • SP-X Imaging and Analysis System
  • Simoa Accelerator Laboratory
  • Homebrew - Custom Assay Development
  • Uman NF-Light

The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.

Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.66%
Tags
none
Rhea-AI Summary

The FDA's recent approval of tofersen for treating SOD1-ALS marks a significant milestone, supported by compelling blood-based neurofilament light chain (NfL) measurements. This is the first instance of a blood biomarker being utilized as a surrogate endpoint for accelerated drug approval in neurology. Tofersen, which reduces the overproduction of SOD1 protein, demonstrated trends toward clinical benefit despite not significantly slowing disease progression in Phase III trials. The approach of using NfL measurements opens new avenues for neurodegenerative disease research and treatment, potentially impacting various conditions like Alzheimer's and multiple sclerosis. Quanterix Corporation, the developer of the Simoa NfL assay, plays a crucial role in this breakthrough, advancing biomarker use in clinical management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX), a leader in biomarker detection, has announced that CEO Masoud Toloue will present at the Barclays Global Healthcare Conference on March 15, 2023, at 4:35 p.m. EDT. The company will also conduct one-on-one meetings with institutional investors on the same day. Investors can register for a virtual presentation via the provided link. Following the conference, the presentation and webcast will be accessible on Quanterix’s website. Quanterix is recognized for its Simoa® technology, which revolutionizes biomarker detection and supports significant research across various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
-
Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX) announced its financial results for Q4 and the full year ended December 31, 2022. The company reported a Q4 GAAP revenue of $25.8 million, a 14.7% decline from the previous year, while full-year revenue was $105.5 million, down from $110.6 million in 2021. The gross margin for Q4 was 48.8%, improved from 41.1% in Q3 2022. The company reported an operating loss of $22.3 million, influenced by $10 million in restructuring costs. Despite the setbacks, the CEO noted progress in their strategic business realignment and promising advancements in Alzheimer's diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.13%
Tags
none
Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Masoud Toloue, will present at Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. EST. The conference occurs from March 6-8, 2023, at the Boston Marriott Copley Place. Quanterix will host one-on-one meetings with institutional investors during the event. The presentation will be available via live audio webcast, and replays will be accessible afterward on the company's investor relations page. Quanterix specializes in ultrasensitive biomarker detection through its Simoa® technology, contributing to advancements in various fields including neurology and oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
conferences
-
Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX) announced a conference call scheduled for March 6, 2023, at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2022 financial results. The call will be led by Masoud Toloue, President and CEO, and Michael Doyle, CFO. A press release with detailed earnings information will precede the call, available on the Quanterix website. Quanterix specializes in ultrasensitive biomarker detection, leveraging its Simoa® technology for breakthroughs in various disease areas. The company has been a longstanding partner in scientific research, contributing to over 2,000 peer-reviewed journals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
-
Rhea-AI Summary

NATICK, Mass. - Mercy BioAnalytics announced that Dawn Mattoon, PhD, has taken over as Chief Executive Officer, transitioning from her previous role as Chief Operating Officer. Paul Blavin has moved to the position of Vice Chairman of the Board. Dr. Mattoon, who has been with the company for seven months, praised the team's progress in advancing their cancer detection technology. Her experience includes leadership roles in strategic initiatives at companies like Quanterix and Thermo Fisher Scientific. The company focuses on the early detection of cancers, particularly ovarian and lung cancers, through its Mercy Halo liquid biopsy platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
management
Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX) appointed Brian Blaser to its Board of Directors on January 6, 2023. With over 25 years in the in-vitro diagnostics field, including 15 years at Abbott Laboratories, Blaser's leadership experience enhances the board's expertise. He has a proven track record in launching diagnostic products and implementing growth strategies. CEO Masoud Toloue emphasized Blaser's operational excellence, which aligns with Quanterix’s future diagnostics initiatives. Blaser holds an MBA from the Rochester Institute of Technology and a Bachelor's in Mechanical Engineering Technology from the University of Dayton.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.71%
Tags
management

FAQ

What is the current stock price of Quanterix Corporation (QTRX)?

The current stock price of Quanterix Corporation (QTRX) is $10.5 as of December 20, 2024.

What is the market cap of Quanterix Corporation (QTRX)?

The market cap of Quanterix Corporation (QTRX) is approximately 400.3M.

What is the core technology of Quanterix Corporation?

The core technology of Quanterix Corporation is Single Molecule Array (Simoa™) technology, which enables ultra-sensitive detection and quantification of protein biomarkers.

What are some applications of Quanterix's technology?

Quanterix's technology is used in life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.

Who founded Quanterix Corporation?

Quanterix Corporation was founded by Dr. David Walt, who also co-founded Illumina.

What product platforms does Quanterix offer?

Quanterix offers the Simoa platform, Assay Kits, LDTs & Assay Services, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, and more.

What makes Quanterix's diagnostic platform unique?

Quanterix's diagnostic platform is unique for its ability to measure individual proteins at concentrations 1000 times lower than conventional immunoassays.

Is Quanterix publicly traded?

Yes, Quanterix Corporation is publicly traded on NASDAQ under the symbol QTRX.

What significant achievements has Quanterix made recently?

Quanterix has significantly advanced precision health by developing platforms that allow for ultra-sensitive detection of biomarkers.

What fluids can Quanterix's platforms detect biomarkers in?

Quanterix's platforms can detect biomarkers in blood, serum, and other fluids.

Does Quanterix offer custom assay development?

Yes, Quanterix offers Homebrew - Custom Assay Development services.

What is the Simoa Accelerator Laboratory?

The Simoa Accelerator Laboratory is a facility provided by Quanterix for advanced biomarker detection and research.

Quanterix Corporation

Nasdaq:QTRX

QTRX Rankings

QTRX Stock Data

400.29M
35.82M
6.54%
88.66%
5.19%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
BILLERICA